| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
4-Cumylphenol does not have a defined pharmacological target as it is an industrial chemical and research reagent. Studies have shown that 4-cumylphenol can induce lipid accumulation in mouse adipocytes similarly to bisphenol A, and has estrogenic proliferative effects in MCF-7 breast cancer cells. These findings suggest potential endocrine-disrupting activity.
|
|---|---|
| ln Vitro |
In three T3-L1 cells, 4-cumylphenol (1, 5, 10, 20, 40 µM; six days) increases lipid accumulation[3].
In vitro studies have demonstrated that 4-cumylphenol induces lipid accumulation in mouse adipocytes similarly to bisphenol A. It also exhibits estrogenic proliferative effects in MCF-7 breast cancer cells. These in vitro activities suggest that 4-cumylphenol may act as an endocrine disruptor. |
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for 4-Cumylphenol as a therapeutic agent. The compound is used primarily as an industrial chemical and research reagent. It is not administered to animals for pharmacological evaluation. Its applications are limited to industrial and research settings.
|
| Enzyme Assay |
For non-cellular assays, 4-Cumylphenol is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compound can be evaluated in receptor binding assays. Typical protocols involve dissolving the compound in appropriate solvents. Purity: 95-97%. Density: 1.115 g/cm³. Boiling point: 335°C.
|
| Cell Assay |
Cell Viability Assay[3]
Cell Types: 3 T3-L1 cells Tested Concentrations: 1, 5 , 10, 20, 40 µM Incubation Duration: 6 days Experimental Results: Increase lipid accumulation, which peaked at10 µM with a 204% increase. For in vitro cell-based studies, 4-Cumylphenol can be used to assess estrogenic effects and lipid accumulation. Cells such as MCF-7 breast cancer cells and mouse adipocytes are cultured under standard conditions and treated with the compound to evaluate proliferative effects and lipid accumulation. Appropriate controls should be included in the experimental design. |
| Animal Protocol |
For in vivo animal studies, 4-Cumylphenol can be formulated using standard injection vehicles. The compound is a solid at room temperature. Dosing solutions should be freshly prepared and administered according to specific protocols with appropriate control groups. Standard handling procedures for phenolic compounds should be followed.
|
| ADME/Pharmacokinetics |
4-Cumylphenol has a molecular weight of 212.29 and molecular formula C15H16O. It has a density of 1.115 g/cm³, boiling point of 335°C, and melting point of 72-75°C. LogP: 3.7. Storage: keep in a cool, dry place protected from light and moisture. Purity: 95-97%.
|
| Toxicity/Toxicokinetics |
Toxicity Data
LCLo0 (Rat) = 72 mg/m³ Non-human Toxicity Values LD50 (Rat): Oral administration 1770 mg/kg body weight LD50 (Frog): Oral administration 335 mg/kg 4-Cumylphenol is classified with GHS Hazard Statement H302 (harmful if swallowed). Signal word: Warning. Precautionary statements include P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338. The compound is for research use only and not for human consumption. |
| References |
[1]. Yue W, et al. Biodegradation of bisphenol-A polycarbonate plastic by Pseudoxanthomonas sp. strain NyZ600. J Hazard Mater. 2021 Aug 15;416:125775.
[2]. Chiha M, et al. Sonolytic degradation of endocrine disrupting chemical 4-cumylphenol in water. Ultrason Sonochem. 2011 Sep;18(5):943-50. [3]. Ramskov Tetzlaff CN, Svingen T, et al. Bisphenols B, E, F, and S and 4-cumylphenol induce lipid accumulation in mouse adipocytes similarly to bisphenol A. Environ Toxicol. 2020 May;35(5):543-552. |
| Additional Infomation |
4-Cumol is a diarylmethane. It has been reported that ginseng contains 4-cumylphenol, and relevant data exists.
4-Cumylphenol (CAS 599-64-4) is also known as p-cumylphenol, p-(α,α-dimethylbenzyl)phenol, and 4-(2-phenylpropan-2-yl)phenol. It is used in surfactants, phenolic resins, and as a polycarbonate chain terminator. Studies have shown endocrine-disrupting activity. No clinical trials or therapeutic approvals exist. |
| Molecular Formula |
C15H16O
|
|---|---|
| Molecular Weight |
212.29
|
| Exact Mass |
212.12
|
| CAS # |
599-64-4
|
| PubChem CID |
11742
|
| Appearance |
White to tan crystals
Prisms from petroleum ether |
| Density |
1,115 g/cm3
|
| Boiling Point |
335 °C
|
| Melting Point |
74.5 °C
|
| Flash Point |
160 °C
|
| Index of Refraction |
1.587
|
| LogP |
3.718
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
208
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1C([H])=C([H])C(=C([H])C=1[H])C(C([H])([H])[H])(C([H])([H])[H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
QBDSZLJBMIMQRS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H16O/c1-15(2,12-6-4-3-5-7-12)13-8-10-14(16)11-9-13/h3-11,16H,1-2H3
|
| Chemical Name |
4-(2-phenylpropan-2-yl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7105 mL | 23.5527 mL | 47.1054 mL | |
| 5 mM | 0.9421 mL | 4.7105 mL | 9.4211 mL | |
| 10 mM | 0.4711 mL | 2.3553 mL | 4.7105 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
